Concepedia

Daniel Tatosian

DT

17

Publications

701

Citations

13

H-Index

2005

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Cornell University

United States Military Academy

Celerion (United States)

Yonsei University

Daniel Tatosian is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

2005–2020

17

Publications

17

A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers

Daniel Tatosian, Michael L. Shuler · Biotechnology and Bioengineering · 2008 · 145 citations

, , +22

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using <i>In Vitro</i>, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches

Yingying Guo, Xiaoyan Chu, Neil Parrott et al. · Clinical Pharmacology & Therapeutics · 2018 · 113 citations · Full text

, , +17

A comparative study of the binding properties, dipeptidyl peptidase‐4 (<scp>DPP</scp>‐4) inhibitory activity and glucose‐lowering efficacy of the <scp>DPP</scp>‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

Joel P. Berger, Ranabir SinhaRoy, Alessandro Pocai et al. · Endocrinology Diabetes & Metabolism · 2017 · 87 citations · Full text

A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment

Daniel Tatosian, Ka Lai Yee, Zufei Zhang et al. · Clinical Pharmacology & Therapeutics · 2020 · 52 citations

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin

Daniel Tatosian, Ying Guo, Andrea Schaeffer et al. · Diabetes Therapy · 2013 · 47 citations · Full text

Rows per page

1–5 of 17